Medicus Pharma Secures Conditional Nasdaq Listing Compliance After Equity Financings
Medicus Pharma (NASDAQ: MDCX) regained Nasdaq listing compliance after raising $4.25 million in equity and exchanging $10.5 million in debt.
Follow the latest Pfizer Inc. (PFE) news and market headlines alongside the live PFE price. Stay informed on what's moving PFE.
Medicus Pharma (NASDAQ: MDCX) regained Nasdaq listing compliance after raising $4.25 million in equity and exchanging $10.5 million in debt.
Pfizer is scheduled to pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining an 88-year dividend streak. While the company faces a patent cliff, it has a $14.3 billion cash cushion to support dividends. A combination of three major challenges—patent cliff impact, cash-draining acquisition, and significant clinical setbacks—would likely be needed to end the streak, though analysts view this scenario as unlikely.
The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.
The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.
Pfizer signs up to $2.63B licensing deal with Starna Therapeutics for in vivo CAR-T autoimmune therapies, paying $330M upfront.
Deal Terms and Financial DetailsStarna will receive an upfront payment of $330 million.Starna is eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III trial (evERA)1In
The article recommends Pfizer and PepsiCo as overlooked dividend stocks offering yields above 4% in a market focused on AI and growth. Pfizer is diversifying into oncology with strong acquisition-driven growth, while PepsiCo is recovering from weight-loss drug concerns through international expansion and pricing power. Both stocks offer durability and reliable dividend income for long-term investors.
The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.
Invesco Pharmaceuticals ETF (PJP) delivered 36.1% one-year returns with concentrated pharma exposure, significantly outperforming Simplify Health Care ETF (PINK) at 22.7%. PINK offers lower expenses, broader healthcare diversification, and donates profits to breast cancer research, while PJP provides 20+ years of track record but carries sector concentration risk.
The article examines five high-yield dividend stocks that appear riskier than they actually are. Pfizer and Bristol Myers Squibb face normal pharmaceutical industry headwinds from patent expirations but maintain sustainable dividends through strong cash flows. REITs Realty Income and W.P. Carey are pressured by rising interest rates, but historical market adjustments should protect profitability. Hormel Foods, despite slow turnaround progress, has strong financials and backing from the Hormel Foundation, making its dividend safer than its yield suggests.
The article compares Novo Nordisk and Pfizer as investment choices for 2027. Novo Nordisk dominates the high-growth obesity and diabetes treatment markets with blockbuster drugs like Wegovy and Ozempic, but faces pricing pressures and competition from rivals like Eli Lilly. Pfizer offers a diversified portfolio, stronger cash position ($14.3B vs $6.8B), and cheaper valuation, making it the better turnaround bet despite slower growth. Both companies face headwinds from pricing pressures and competitive threats.
Axsome Therapeutics and Moderna represent different biotech investment profiles. Axsome shows strong 54% revenue growth with three marketed drugs and a narrowing path to profitability, trading at conservative valuations (41x forward P/E). Moderna, despite its revolutionary mRNA platform, faces declining COVID vaccine demand and significant losses ($2.8B net loss on $2.5B revenue), trading at a premium 249x forward P/E. The article recommends Axsome as the better 2027 buy due to superior valuation and near-term revenue visibility, while acknowledging Moderna's long-term potential.
As 2026 winds down, the article analyzes four key sector ETFs heading into 2027. Technology stocks have pulled back 14% from October highs after AI companies missed earnings, but the sector remains reasonably valued. Financial stocks are mixed, with insurance outperforming while banks struggle amid tepid loan demand. Energy stocks surged 40% YTD on oil prices but face headwinds as crude may have peaked around $90/barrel. Healthcare stocks are up 21% but appear slightly overvalued at current levels.
Pfizer will stop selling Premarin cream and tablets in Canada after an internal review, adding strain to ongoing menopause drug shortages.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
Moderna shares gained 3% following better-than-expected Q3 2026 earnings and raised full-year revenue guidance to 15-25% growth, driven by stronger international COVID-19 vaccine sales. The company's oncology pipeline, particularly its personalized cancer therapy intismeran developed with Merck, showed promising phase III results with a 42% reduction in recurrence or death risk. Despite premium valuation and ongoing cash burn concerns, Moderna maintains a Zacks Rank #2 (Buy) rating, supported by expanding respiratory vaccine portfolio and oncology opportunities.
Pfizer and Blackstone Life Sciences signed a $1.5 billion deal to fund berobenatide, a monthly GLP-1 obesity drug entering 10 Phase 3 trials in 2026.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to PFE, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.